Slide 1: Third Quarter 2010 Earnings Conference Call
1 TELEFLEX INCORPORATED THIRD QUARTER 2010 EARNINGS CONFERENCE CALL Exhibit 99.1
Slide 2: Forward-Looking Statements/Additional Notes
2 2 2 2 Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, forecasted 2010 total revenue, total company gross margins, total company R&D expense, total company operating margins and effect
Slide 3: Conference Call Logistics
3 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 617- 801-6888, pass code number 91604182
Slide 4: Quarter & Year Highlights
4 QUARTER & YEAR HIGHLIGHTS
Slide 5: September Quarter-to-Date Highlights
5 September Quarter-to-Date Highlights Revenue of $443 million - up 1% as reported; up 4% constant currency On a constant currency basis: Medical revenue growth of 2% Aerospace revenue growth of 5% Commercial revenue growth of 15% Adjusted gross margins of 45.8% Increase of 120 basis points as compa
Slide 6: September Quarter-to-Date Highlights
6 September Quarter-to-Date Highlights Received approval of all Certificates to Foreign Governments from FDA New product introductions continue Received 510(k) market clearance for ArrowEVOLUTION(tm) PICC with Chlorag+ard(tm) Partnered with Access Scientific to become the U.S. distributor of The PIC
Slide 7: September Year-to-Date Highlights
7 September Year-to-Date Highlights Revenue of $1,326 million - up 2% as reported; up 3% constant currency On a constant currency basis: Medical revenue growth of 1% Aerospace revenue growth of 5% Commercial revenue growth of 19% Adjusted gross margins of 45.7% Increase of 90 basis points as compare
Slide 8: Third Quarter Segment Revenue Review
8 THIRD QUARTER SEGMENT REVENUE REVIEW
Slide 9: Medical
9 Medical Critical Care Surgical Care Cardiac Care OEM 0.66 0.18 0.05 0.11 North America EMEA Asia / Latin America 0.53 0.34 0.13 Q3'10 Revenue Sales = $345.1 million, up 2% constant currency Q3'10 Constant Currency Revenue Results Critical Care: $226.2 million, flat Surgical Care: $61.6 million, up
Slide 10: Critical Care
10 Critical Care Vascular Access Respiratory Urology Anesthesia 0.44 0.18 0.15 0.23 North America EMEA Asia / Latin America 0.5 0.36 0.14 Q3'10 Revenue Vascular decline of 4% Respiratory sales increase 7% Urology sales up 1% Anesthesia sales up 5% End Market Growth Drivers Infection prevention - ant
Slide 11: Surgical Care
11 Surgical Care North America EMEA Asia / Latin America 0.53 0.35 0.12 Q3'10 Revenue Higher gross margin ligation sales more than offset reduced general instrument and chest drainage sales Minimally invasive surgical techniques Technology / product advances Emerging markets Instruments Ligation Clo
Slide 12: Cardiac Care
12 Cardiac Care North America EMEA Asia / Latin America 0.31 0.46 0.23 Q3'10 Revenue Increased sales of pumps and catheters in European markets Emerging markets Technology innovation Aging population Pumps Catheters 0.3 0.7 End Market Growth Drivers Sales = $17.4 million, up 6% constant currency Q3'
Slide 13: OEM
13 OEM Q3'10 Revenue Strength of specialty product sales continue Somewhat offset by weakness of orthopedic product sales Technology innovation Speed to market Demographics Increased regulatory scrutiny on suppliers Specialty Products Orthopedic Products 0.8 0.2 North America EMEA 0.85 0.15 End Mark
Slide 14: Aerospace
14 Aerospace Q3'10 Revenue Narrow-body cargo loading system unit volume up OEM wide-body sales down Improved actuator and spare sales Container sales up due to slightly improved end-market conditions / loosened capital spending constraints Increase in air travel and flight hours Boeing 747-8 platfor
Slide 15: Commercial
15 Commercial Q3'10 Revenue Sales = $51.1 million, up 15% constant currency Significant increase in higher gross margin aftermarket marine products, as well as sales to OEM manufacturers Sales of modern burner unit to U.S. military down, as expected Global economy Marine 1 End Market Growth Drivers
Slide 16: Financial Review
FINANCIAL REVIEW Teleflex:
Slide 17: Third Quarter Income Statement from Continuing Operations
17 Third Quarter Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 18: Third Quarter EPS Reconciliation from Continuing Operations
18 Third Quarter EPS Reconciliation from Continuing Operations
Slide 19: Year-to-Date Income Statement from Continuing Operations
19 Year-to-Date Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 20: Year-to-Date EPS Reconciliation from Continuing Operations
20 Year-to-Date EPS Reconciliation from Continuing Operations
Slide 21: Year-to-Date Cash Flow Summary
21 Year-to-Date Cash Flow Summary ($ in Millions)
Slide 22: 2010 Outlook
2 2010 Outlook current FY 10 outlook ‘ata! Revenue Talal Company Grose Margine ‘etal campany Reo ‘Tela! Gempany Operating Margie restive Tax Rate ‘Asjustes EP8 trem Gentiuing Operations ‘Arrertzation Expense per ehare ste count on cenvertole nates ‘Amartzation st ‘Adjusted Coen EPs: cach Flow fremGe
Slide 23: Question & Answer
QUESTION & ANSWER Teleflex:
Slide 24: Appendices
APPENDICES Teleflex:
Slide 25: Appendix A - Medical Segment Review
25 Appendix A - Medical Segment Review
Slide 26: Appendix B - Aerospace Segment Review
26 Appendix B - Aerospace Segment Review
Slide 27: Appendix C - Commercial Segment Review
27 Appendix C - Commercial Segment Review
Slide 28: Appendix D - Reconciliation of Medical Operating Profit and Margins
28 Appendix D - Reconciliation of Medical Operating Profit and Margins
Slide 29: Appendix E - Reconciliation of Teleflex Gross Profit and Margins
29 Appendix E - Reconciliation of Teleflex Gross Profit and Margins
Slide 30: Appendix F - Reconciliation of Selling and Administrative Expenses
30 Appendix F - Reconciliation of Teleflex Selling and Administrative Expenses
Slide 31: Appendix G - Reconciliation of Teleflex Operating Expenses
31 Appendix G - Reconciliation of Teleflex Operating Expenses
Slide 32: Appendix H - Special Charge Income Statement Classification Summary
32 Appendix H - Special Charge Income Statement Classification Summary
Slide 33: Appendix I - Quarter-to-Date Reconciliation of Cash EPS
33 Appendix I - Quarter-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 34: Appendix J - Year-to-Date Reconciliation of Cash EPS
34 Appendix J - Year-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 35: Appendix K - Medical Constant Currency Revenue Growth Reconciliation
35 Appendix K - Quarter and Year-to-Date Reconciliation of Medical Constant Currency Revenue Growth
Slide 36: Appendix L - Teleflex Constant Currency Revenue Growth Reconciliation
36 Appendix L - Quarter and Year-to-Date Reconciliation of Teleflex Incorporated Constant Currency Revenue Growth % Increase / (Decrease) 2010 vs. 2009 Medical Aerospace Commercial Total Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Core growth 2